SMMT - Summit Therapeutics Inc
IEX Last Trade
13
0.140 1.077%
Share volume: 2,106,166
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$12.86
0.14
1.09%
Fundamental analysis
25%
Profitability
25%
Dept financing
12%
Liquidity
75%
Performance
16%
Performance
5 Days
-0.76%
1 Month
21.42%
3 Months
342.25%
6 Months
186.53%
1 Year
650.29%
2 Year
1,009.40%
Key data
Stock price
$13.00
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.52 - $14.25
52 WEEK CHANGE
$6.96
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website: summitplc.com
Employees: 98
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: summitplc.com
Employees: 98
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.
Recent news